Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 230-242

  Xylinas, Evanguelos ^a   Kluth, Luis A ^a   Lotan, Yair ^c   Daneshmand, Siamak ^d   Rieken, Malte ^a   Karakiewicz, Pierre I ^e   Shariat, Shahrokh F ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biomarker; Bladder cancer; Blood based; Molecular marker; Prediction; Prognosis; Survival; Tissue based; Urothelial carcinoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BIOLOGICAL MARKER; CASPASE 3; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HORMONE RECEPTOR; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAS PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SURVIVIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULOTROPIN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY DENSITY; CYSTECTOMY; HUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; UROTHELIAL CARCINOMA OF THE BLADDER; BLADDER TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

CARCINOMA, TRANSITIONAL CELL; HUMANS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84897073946     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.009     Document Type: Article

References (111)

1. Karakiewicz P.I., Shariat S.F., Palapattu G.S., Gilad A.E., Lotan Y., Rogers C.G., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006, 176(4 Pt 1):1354-1361. [discussion 1361-1352].
2. Shariat S.F., Karakiewicz P.I., Palapattu G.S., Amiel G.E., Lotan Y., Rogers C.G., et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006, 12(22):6663-6676.
3. Bochner B.H., Kattan M.W., Vora K.C. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006, 24(24):3967-3972.
4. Rink M., Shariat S.F. Can we apply nomograms derived in the United States to European patients? Yes, we can!. Eur Urol 2011, [Epub ahead of print].
5. Barbieri C.E., Lotan Y., Lee R.K., Sonpavde G., Karakiewicz P.I., et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol 2010, 62(3):241-258.
6. Matsushita K., Cha E.K., Matsumoto K., Baba S., Chromecki T.F., Fajkovic H., et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol 2011, [Epub ahead of print].
7. Kim Y.K., Kim W.J. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 2009, 16(1):17-22.
8. Shariat S.F., Karakiewicz P.I., Ashfaq R., Lerner S.P., Palapattu G.S., Cote R.J., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008, 112(2):315-325.
9. Shariat S.F., Karam J.A., Lerner S.P. Molecular markers in bladder cancer. Curr Opin Urol 2008, 18(1):1-8.
10. Shariat S.F., Tilki D. Bladder cancer: nomogram aids clinical decision making after radical cystectomy. Nat Rev Urol 2010, 7(4):182-184.
11. Vrooman O.P., Witjes J.A. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 2009, 16(3):234-243.
12. Kamat A.M., Hegarty P.K., Gee J.R., Clark P.E., Svatek R.S., Hegarty N., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 2013, 63(1):4-15.
13. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408(6810):307-310.
14. Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.C., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331(19):1259-1264.
15. Grossman H.B., Liebert M., Antelo M., Dinney C.P., Hu S.X., Palmer J.L., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998, 4(4):829-834.
16. Shariat S.F., Tokunaga H., Zhou J., Kim J., Ayala G.E., Benedict W.F., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004, 22(6):1014-1024.
17. Stein J.P., Ginsberg D.A., Grossfeld G.D., Chatterjee S.J., Esrig D., Dickinson M.G., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998, 90(14):1072-1079.
18. Chatterjee S.J., Datar R., Youssefzadeh D., George B., Goebell P.J., Stein J.P., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004, 22(6):1007-1013.
19. Malats N., Bustos A., Nascimento C.M., Fernandez F., Rivas M., Puente D., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005, 6(9):678-686.
20. Shariat S.F., Lotan Y., Karakiewicz P.I., Ashfaq R., Isbarn H., Fradet Y., et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009, 182(3):907-913.
21. Shariat S.F., Zlotta A.R., Ashfaq R., Sagalowsky A.I., Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007, 20(4):445-459.
22. Shariat S.F., Bolenz C., Karakiewicz P.I., Fradet Y., Ashfaq R., Bastian P.J., et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010, 105(4):489-495.
23. Shariat S.F., Chade D.C., Karakiewicz P.I., Ashfaq R., Isbarn H., Fradet Y., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010, 183(1):68-75.
24. Neuzillet Y., Paoletti X., Ouerhani S., Mongiat-Artus P., Soliman H., de The H., et al. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One 2012, 7(12):e48993.
25. Mitra A.P., Castelao J.E., Hawes D., Tsao-Wei D.D., Jiang X., Shi S.R., et al. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer 2013, 119(4):756-765.
26. Shariat S.F., Bolenz C., Godoy G., Fradet Y., Ashfaq R., Karakiewicz P.I., et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009, 182(1):78-84. [discussion 84].
27. Goebell P.J., Groshen S.G., Schmitz-Dräger B.J. (ISBC) IS-IoBC: p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010, 28(4):377-388.
28. Dalbagni G., Parekh D.J., Ben-Porat L., Potenzoni M., Herr H.W., Reuter V.E. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007, 99(2):281-285.
29. Esuvaranathan K., Chiong E., Thamboo T.P., Chan Y.H., Kamaraj R., Mahendran R., et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007, 109(6):1097-1105.
30. Moonen P.M., van Balken-Ory B., Kiemeney L.A., Schalken J.A., Witjes J.A. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007, 177(1):80-83.
31. Cormio L., Tolve I., Annese P., Saracino A., Zamparese R., Sanguedolce F., et al. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009, 29(10):4201-4204.
32. Oh J.J., Ji S.H., Choi D.K., Gong I.H., Kim T.H., Park D.S. A six-week course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53. Oncology 2010, 79(5-6):440-446.
33. Park J., Song C., Shin E., Hong J.H., Kim C.S., Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?. Urol Oncol 2011, 31:849-856.
34. Stadler W.M., Lerner S.P., Groshen S., Stein J.P., Shi S.R., Raghavan D., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011.
35. Lenz P., Pfeiffer R., Baris D., Schned A.R., Takikita M., Poscablo M.C., et al. Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev 2012, 21(9):1555-1564.
36. Margulis V., Shariat S.F., Ashfaq R., Sagalowsky A.I., Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006, 12(24):7369-7373.
37. Margulis V., Lotan Y., Karakiewicz P.I., Fradet Y., Ashfaq R., Capitanio U., et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009, 101(2):114-119.
38. Behnsawy H.M., Miyake H., Abdalla M.A., Sayed M.A., Ahmed A.E., Fujisawa M. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 2009.
39. Harada K., Ogden G.R. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 2000, 36(1):3-7.
40. Rebouissou S., Herault A., Letouze E., Neuzillet Y., Laplanche A., Ofualuka K., et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 2012, 227(3):315-324.
41. Shariat S.F., Ashfaq R., Sagalowsky A.I., Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006, 37(12):1568-1576.
42. Del Pizzo J.J., Borkowski A., Jacobs S.C., Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999, 155(4):1129-1136.
43. Margulis V., Lotan Y., Shariat S.F. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008, 26(1):59-65.
44. Yamana K., Bilim V., Hara N., Kasahara T., Itoi T., Maruyama R., et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005, 93(5):544-551.
45. Arai M., Sasaki A., Saito N., Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int 2005, 55(3):122-129.
46. Burton P.B., Anderson C.J., Corbishly C.M. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 2000, 343(19):1418-1420.
47. Giannopoulou I., Nakopoulou L., Zervas A., Lazaris A.C., Stravodimos C., Giannopoulos A., et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002, 30(5):342-345.
48. Karam J.A., Lotan Y., Karakiewicz P.I., Ashfaq R., Sagalowsky A.I., Roehrborn C.G., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007, 8(2):128-136.
49. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22(53):8581-8589.
50. Schultz I.J., Kiemeney L.A., Karthaus H.F., Witjes J.A., Willems J.L., Swinkels D.W., et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004, 50(8):1425-1428.
51. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004, 171(2 Pt 1):626-630.
52. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Alterieri D.C. Urine detection of survivin and diagnosis of bladder cancer. Jama 2001, 285(3):324-328.
53. Shariat S.F., Ashfaq R., Karakiewicz P.I., Saeedi O., Sagalowsky A.I., Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007, 109(6):1106-1113.
54. Shariat S.F., Karakiewicz P.I., Godoy G., Karam J.A., Ashfaq R., Fradet Y., et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 2009, 15(22):7012-7019.
55. Salz W., Eisenberg D., Plescia J., Garlick D.S., Weiss R.M., Wu X.R., et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005, 65(9):3531-3534.
56. Xi R.C., Sheng Y.R., Chen W.H., Sheng L., Gang J.J., Tong Z., et al. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 2012.
57. Bochner B.H., Cote R.J., Weidner N., Groshen S., Chen S.C., Skinner D.G., et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87(21):1603-1612.
58. Jaeger T.M., Weidner N., Chew K., Moore D.H., Kerschmann R.L., Waldman F.M., et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995, 154(1):69-71.
59. Inoue K., Slaton J.W., Karashima T., Yoshikawa C., Shuin T., Sweeney P., et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6(12):4866-4873.
60. Shariat S.F., Youssef R.F., Gupta A., Chade D.C., Karakiewicz P.I., Isbarn H., et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010, 183(5):1744-1750.
61. Ajili F., Kacem M., Tounsi H., Darouiche A., Enayfer E., Chebi M., et al. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34. Ultrastruct Pathol 2012, 36(5):336-342.
62. Das K., Zhao Y., Sugiono M., Lau W., Tan P.H., Cheng C. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol 2007, 25(4):317-321.
63. Herrmann E., Eltze E., Bierer S., Kopke T., Gorge T., Neumann J., et al. VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res 2007, 27(5A):3127-3133.
64. Miyata Y., Kanda S., Ohba K., Nomata K., Hayashida Y., Eguchi J., et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006, 12(3 Pt 1):800-806.
65. Zu X., Tang Z., Li Y., Gao N., Ding J., Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006, 98(5):1090-1093.
66. Elfiky A.A., Rosenberg J.E. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009, 11(3):244-249.
67. Grossfeld G.D., Ginsberg D.A., Stein J.P., Bochner B.H., Esrig D., Groshen S., et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997, 89(3):219-227.
68. Miyake H., Hara I., Gohji K., Yoshimura K., Arakawa S., Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998, 123(2):121-126.
69. Mitra A.P., Cote R.J. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009, 4:251-285.
70. Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007, 25(6):581-593.
71. van Rhijn B.W., Zuiverloon T.C., Vis A.N., Radvanyi F., van Leenders G.J., Ooms B.C., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010, 58(3):433-441.
72. Mellon J.K., Lunec J., Wright C., Horne C.H., Kelly P., Neal D.E. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996, 155(1):321-326.
73. McHugh L.A., Sayan A.E., Mejlvang J., Griffiths T.R., Sun Y., Manson M.M., et al. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 2009, 34(4):1155-1163.
74. McHugh L.A., Griffiths T.R., Kriajevska M., Symonds R.P., Mellon J.K. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology 2004, 63(4):619-624.
75. Rajjayabun P.H., Keegan P.E., Lunec J., Mellon J.K. erbB receptor expression patterns in human bladder cancer. Urology 2005, 66(1):196-200.
76. Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24(33):5218-5225.
77. Korkolopoulou P., Levidou G., Trigka E.A., Prekete N., Karlou M., Thymara I., et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 2012, 110(11 Pt C):E1237-E1248.
78. Bartholomeusz C., Gonzalez-Angulo A.M. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012, 16(1):121-130.
79. Fajkovic H., Halpern J.A., Cha E.K., Bahadori A., Chromecki T.F., Karakiewicz P.I., et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011, 29(4):457-463.
80. Jimenez R.E., Hussain M., Bianco F.J., Vaishampayan U., Tabazcka P., Sakr W.A., et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001, 7(8):2440-2447.
81. Kassouf W., Black P.C., Tuziak T., Bondaruk J., Lee S., Brown G.A., et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008, 179(1):353-358.
82. Kruger S., Weitsch G., Buttner H., Matthiensen A., Bohmer T., Marquardt T., et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002, 102(5):514-518.
83. Lae M., Couturier J., Oudard S., Radvanyi F., Beuzeboc P., Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010, 21(4):815-819.
84. Fleischmann A., Rotzer D., Seiler R., Studer U.E., Thalmann G.N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011, 60(2):350-357.
85. Bolenz C., Shariat S.F., Karakiewicz P.I., Ashfaq R., Ho R., Sagalowsky A.I., et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010, 106(8):1216-1222.
86. Boorjian S., Ugras S., Mongan N.P., Gudas L.J., You X., Tickoo S.K., et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004, 64(2):383-388.
87. Tuygun C., Kankaya D., Imamoglu A., Sertcelik A., Zengin K., Oktay M., et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011, 29(1):43-51.
88. Mir C., Shariat S.F., van der Kwast T.H., Ashfaq R., Lotan Y., Evans A., et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 2011, 108(1):24-30.
89. Bolenz C., Lotan Y., Ashfaq R., Shariat S.F. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 2009, 56(6):1093-1095.
90. Shariat S.F., Karakiewicz P.I., Ashfaq R., Isbarn H., Fradet Y., Bastian P.J., et al. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J Urol 2008, 179(4):578.
91. Shariat S.F., Kim J., Nguyen C., Wheeler T.M., Lerner S.P., Slawin K.M. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology 2003, 61(2):359-364.
92. Byrne R.R., Shariat S.F., Brown R., Kattan M.W., Morton R.A.J.R., Wheeler T.M., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001, 165(5):1473-1479.
93. Shariat S.F., Monoski M.A., Andrews B., Wheeler T.M., Lerner S.P., Slawin K.M. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 2003, 61(5):1053-1058.
94. Andrews B., Shariat S.F., Kim J.-H., Wheeler T.M., Slawin K.M., Lerner S.P. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002, 167(3):1475-1481.
95. Kim J.H., Shariat S.F., Kim I.Y., Menesses-Diaz A., Tokunaga H., Wheeler T.M., et al. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92(6):1475-1483.
96. Shariat S.F., Kim J.H., Andrews B., Kattan M.W., Wheeler T.M., Kim I.Y., et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92(12):2985-2992.
97. Guan K.-P., Ye H.-Y., Yan Z., Wang Y., Hou S.-K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61(4):719-723.
98. Vasala K., Pääkkö P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003, 62(5):952-957.
99. Gallagher D.J., Milowsky M.I., Ishill N., Trout A., Boyle M.G., Riches J., et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol 2009, 20(2):305-308.
100. Rink M., Chun F.K., Dahlem R., Soave A., Minner S., Hansen J., et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol 2012, 61(4):810-817.
101. Castillejo A., Rothman N., Murta-Nascimento C., Malats N., Garcia-Closas M., Gomez-Martinez A., et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009, 124(3):608-613.
102. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274(31):21491-21494.
103. Cornelius L.A., Nehring L.C., Harding E., Bolanowski M., Welgus H.G., Kobayashi D.K., et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998, 161(12):6845-6852.
104. Ito T.-K., Ishii G., Saito S., Yano K., Hoshino A., Suzuki T., et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009, 113(10):2363-2369.
105. Svatek R.S., Shah J.B., Xing J., Chang D., Lin J., Mcconkey D.J., et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 2010, 116(19):4513-4519.
106. Szarvas T., Becker M., Vom Dorp F., Gethmann C., Tötsch M., Bánkfalvi A., et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 2010, 101(5):1300-1308.
107. Szarvas T., Singer B.B., Becker M., Vom Dorp F., Jager T., Szendroi A., et al. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int 2011, 107(7):1069-1073.
108. Szarvas T., Jager T., Becker M., Tschirdewahn S., Niedworok C., Kovalszky I., et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res 2011, 17(2):325-332.
109. Popov Z., Gil-Diez de Medina S., Lefrere-Belda M.A., Hoznek A., Bastuji-Garin S., Abbou C.C., et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000, 83(2):209-214.
110. Byrne R.R., Shariat S.F., Brown R., Kattan M.W., Morton R.J., Wheeler T.M., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001, 165(5):1473-1479.
111. Shariat S.F., Pahlavan S., Baseman A.G., Brown R.M., Green A.E., Wheeler T.M., et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001, 57(1):60-65.